Navigation Links
Controversial medication may decrease spasms for infants with epilepsy
Date:2/2/2009

Helsinki, Finland February 02, 2009 The antiepileptic drug vigabatrin (VGB) has been shown to be one of the best treatments against a special form of epilepsy in infants, called infantile spasm. However, its use has been limited in many countries because it has been shown to cause a permanent narrowing of visual fields in approximately 40 percent of adults who have been exposed at school age or later. A new study published in Epilepsia examined school-aged children who had been treated with VGB in infancy. The findings showed normal visual fields in 15 of the 16 children studied children.

While VGB is an effective drug for infantile spasms, there have been no previous reports on later visual field testing after treatment in infancy. This study used a form of peripheral vision testing, called kinetic perimetry, which is effective in detecting peripheral field defects typical of VGB toxicity, and produces more reliable results in children.

Vigabatrin treatment began at a mean age of 7.6 months, and the mean duration of therapy was 21 months, with a mean cumulative dose of 655 grams. Three of the children had been previously treated with another anti-epileptic drug (AED), five had received only hormonal treatment, and eight children had never been treated with any form of AED.

The findings show that the risk of permanent visual field defects caused by VGB may be lower for treatments in infants than in adults. Results showed that 15 children had normal visual fields and mild visual field loss was observed in one child who had been treated with VGB for 19 months and received a cumulative dose of 572 grams. This frequency is lower than previous observations using kinetic perimetry in older children or adults.

The cumulative VGB doses and treatment durations in the study were, on average, lower than in previous studies, which correspond to the much younger age and weight of the tested patients.

"Our results may
'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.net
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Controversial Chemical Lingers Longer in the Body: Study
2. Rochester study raises new questions about controversial plastics chemical
3. American Association for Homecare Criticizes Release of Controversial Medicare Bidding Rule in Final Hours of Bush Administration
4. George Will Column Misguided in Touting Competitive Bidding as a Medicare Solution; Controversial Bidding Program is Actually Anti-Competitive and Lowers Quality of Care and Access to Care for Seniors and Disabled
5. Controversial New Pool & Spa Safety Act Will Create Public Pool Closures Nationwide
6. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
7. 132 Members of Congress Urge One-Year Delay in Controversial Medicare Bidding Program for Home Medical Equipment
8. Californians Against Assisted Suicide - Controversial Bill, AB 2747 Narrowly Passes Assembly
9. Controversial shoulder surgery for first-time dislocation proven effective long-term
10. Controversial theory of Alzheimers origin funded
11. Controversial New Report Details Successes and Challenges as the Microcredit Movement Escalates Its Battle With Poverty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... M. D. Anderson Cancer Center will hold the ... December 6-7, to bring together internationally recognized breast ... present new clinical discoveries and participate in educational ... management of this rare but deadly disease. , ...
... fibrosis in first 6 months appears most effective, Australian ... It may be possible to control the progression of ... the disease in infants, according to Australian researchers. , ... can start as early as infancy, even though lung ...
... Teenager and His Family , , ... his 13 years, Dustin Monk will have reason to smile this ... ( www.thescooterstore.com ), Dustin will finally have the mobility and independence ... Today, just weeks after Dustin,s father, Danny Monk, contacted The ...
... those denied under current protocols, study says , , FRIDAY, ... who don,t meet criteria used to select transplant patients could ... Italian study. , The Milan criteria specifies that liver cancer ... in diameter, or three or fewer tumors, each no more ...
... Shot , , , ... County is the North Central region,s first state laboratory-confirmed case of ... , "Peak flu season is quickly ... importance of getting vaccinated. It,s the best way to protect ...
... Devices, Inc. (ADI) took part in the ... December 4-5, 2008, in Cambridge, Mass. Analog ... about healthcare market segmentation and trends affecting ... Healthcare Team Technology Director Tom O’Dwyer participated ...
Cached Medicine News:Health News:M. D. Anderson to hold first international conference on inflammatory breast cancer 2Health News:Aggressive Therapy May Stem CF Progression in Infants 2Health News:The SCOOTER Store Donates Power Wheelchair to Texas Teenager With Rare Genetic Disorders 2Health News:The SCOOTER Store Donates Power Wheelchair to Texas Teenager With Rare Genetic Disorders 3Health News:New Criteria Could Expand Number of Liver Transplant Candidates 2Health News:Health Department Reports North Central Region's First Lab-Confirmed Flu Case of the Season 2Health News: Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 2Health News: Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 3Health News: Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 4
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
250L...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: